Makers of seven of 10 top drugs in the U.S. hiked those drugs’ prices substantially in 2020 with no new evidence of improved safety or effectiveness, led by AbbVie’s anti-inflammatory blockbuster Humira, an influential drug pricing watchdog group says.
The
…
Congressional debate over lowering drug prices has shifted to the U.S. Senate following House passage of the $1.75 trillion Build Back Better social spending bill on Friday.
Congress has been on break this week for the Thanksgiving holiday. It returns
…
Q: Where did you grow up?
Conway, Pennsylvania (approximately 20 miles NW of Pittsburgh). I bleed black and gold – yes, I even cheer for the Pirates!
Q: Where did you go to college/graduate school?
I received both my pharmacy (B.S.Ph.) and law (J.D.) degrees from Ohio Northern University.
Q: What are your favorites?
Food: It
…
Drug manufacturer Novo Nordisk late yesterday appealed a federal district judge’s Nov. 5 joint ruling in its and fellow manufacturer Sanofi’s 340B contract pharmacy lawsuits. Sanofi filed its appeal earlier yesterday.
Novo Nordisk’s notice of appeal, like Sanofi’s, is
…
Drug manufacturer Sanofi today gave notice that it is appealing a federal district judge’s Nov. 5 orders and opinions in its 340B contract pharmacy lawsuit.
Sanofi’s one-sentence Nov. 19 notification to the federal government defendants and U.S. Chief District
…
The U.S. Health Resources and Services Administration (HRSA) yesterday asked the White House to review and approve a 340B administrative dispute resolution (ADR) proposed regulation for publication in the Federal Register.
The proposed rule’s purpose is unknown. HRSA published a
…
Drug manufacturer Lilly’s appeal of a federal district judge’s ruling late last month in the company’s 340B contract pharmacy lawsuit has hit a procedural snag.
In an unsigned pair of orders on Tuesday, the federal appeals court in Chicago questioned
…
A Kansas Republican congressman said on Capitol Hill yesterday that pharmacy benefit managers (PBMs) are taking away health centers and other safety net providers’ 340B savings and driving up their costs.
340B health centers and other providers “are reporting that
…
HIV care professionals are warning the public that threats to 340B drug discount savings “will compromise access to affordable care, treatment, and prevention services for underserved people with and at risk for HIV.”
The American Academy of HIV Medicine, the
…
The U.S. Health Resources and Services Administration (HRSA) has reconfirmed that it is auditing 340B covered entities for program compliance both remotely and in-person this fiscal year.
HRSA told 340B Report in mid-September that in October it would resume
…
×
*Sign up for news summaries and alerts from 340B Report
